甲磺酸溴隱亭
中文名稱 | 甲磺酸溴隱亭 |
---|---|
中文同義詞 | 甲磺酸溴隱亭;2-溴-alpha-麥角環(huán)肽甲磺酸鹽;2-溴-Α-麥角隱亭甲磺酸鹽;甲黃酸溴麥角環(huán)肽;甲磺酸溴隱亭/甲黃酸溴麥角環(huán)肽;(6AR,9R)-5-溴-N-((2R,5S,10AS,10BS)-10B-羥基-5-異丁基-2-異丙基-3,6-二氧八氫-2H-惡唑[3,2-A]吡咯并[2,1-C]吡嗪-2-基)-7-甲基-4,6,6A,7,8,9-六氫吲哚并[4,3-FG]喹啉-9-甲酰胺甲磺酸鹽;甲磺酸溴隱亭 USP標(biāo)準(zhǔn)品;甲磺酸溴隱亭 EP標(biāo)準(zhǔn)品 |
英文名稱 | Bromocriptine mesylate |
英文同義詞 | (5'A)-2-BROMO-12'-HYDROXY-2'-(1-METHYLETHYL)-5'-(2-METHYLPROPYL)ERGOTAMAN-3',6',18-TRIONE MESYLATE;(+)-BROMOCRIPTINE MESYLATE;BROMOCRIPTINE MESYLATE;(+)-BROMOCRIPTINE METHANESULFONATE;BROMOCRIPTINE METHANESULPHONATE;BROMOCRYPTINE MESYLATE METHANESULFONATE SALT;(+)-2-BROMO-12'-HYDROXY-2'-(1-METHYLETHYL)-5'-(2-METHYLPROPYL)-ERGOTAMAN-3',6',18-TRIONE METHANESULFONATE;(+)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6'-18-trione methanesulfonate salt |
CAS號(hào) | 22260-51-1 |
分子式 | C33H44BrN5O8S |
分子量 | 750.7 |
EINECS號(hào) | 244-881-1 |
相關(guān)類別 | 醫(yī)藥原料藥;醫(yī)用原料;醫(yī)藥原料;醫(yī)藥原料;原料藥;原料;化學(xué)試劑;試劑;試劑盒-細(xì)胞分析試劑盒;化學(xué)試劑-精細(xì)化工;PARLODEL;Aromatics;Dopamine receptor;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals |
Mol文件 | 22260-51-1.mol |
結(jié)構(gòu)式 | ![]() |
甲磺酸溴隱亭 性質(zhì)
熔點(diǎn) | 192-196° (dec) |
---|---|
比旋光度 | D20 +95° (c = 1 in methanol-methylene chloride) |
儲(chǔ)存條件 | 2-8°C |
溶解度 | H2O:0.8 mg/mL |
形態(tài) | 固體 |
酸度系數(shù)(pKa) | 4.90(at 25℃) |
顏色 | 白色 |
旋光性 (optical activity) | [α]20/D +95°, c = 1 in methanol: methylene chloride (1:1)(lit.) |
水溶解性 | H2O: 0.8mg/mL ethanol: 23mg/mL |
Merck | 13,1400 |
BRN | 4115238 |
穩(wěn)定性 | 從購(gòu)買之日起 2 年內(nèi)保持穩(wěn)定。 DMSO 或乙醇溶液可在 -20°C 下保存長(zhǎng)達(dá) 3 個(gè)月 |
InChIKey | NOJMTMIRQRDZMT-JGYCFGIMSA-N |
CAS 數(shù)據(jù)庫(kù) | 22260-51-1(CAS DataBase Reference) |
1)溴隱亭的合成
將α-麥角隱亭12g(20.8mmoL)和二氯甲烷120mL加入反應(yīng)瓶中,攪拌溶清后依次加入5,5-二溴巴比妥酸3.69g(12.9mmoL)、33%氫溴酸的冰乙酸溶液0.2mL,控溫25~30℃反應(yīng)5~6h,過濾,濾液依次用1moL/L的硫代硫酸鈉(30mL),5%的碳酸氫鈉溶液(30mL),20%氯化鈉溶液(30mL)洗滌。有機(jī)相用無水硫酸鎂干燥,過濾,并加入硅膠36g濃縮將溶劑完全拉干。柱層析:流動(dòng)相先為二氯甲烷,后為V(二氯甲烷)∶V(丙酮)=6∶1的混合溶液。得10.6g溴隱亭,收率78%。
2)甲磺酸溴隱亭的合成
將溴隱亭6.0g用二氯甲烷120mL溶清后加入2-丁酮200mL,控制內(nèi)溫20~30℃,加入甲磺酸1.14g,生成結(jié)晶型沉淀,攪拌1h。濾出固體,用2-丁酮30mL洗滌,干燥得6.13g甲磺酸溴隱亭,收率86%。
Bromocriptine mesylate 是一種有效的多巴胺 D2/D3 受體激動(dòng)劑,結(jié)合多巴胺 D2 受體,pKi 為 8.05±0.2。pKi: 8.05±0.2 (dopamine D2 receptor)
Bromocriptine stimulates [ 35 S]-GTPγS binding at D2 dopamine receptor expressed in CHO cells with pEC 50 of 8.15±0.05. Bromocriptine also is a strong inhibitor of brain nitric oxide synthase. The ergot alkaloid Bromocriptine (BKT) is found to act as a strong inhibitor of purified neuronal nitric oxide synthase (NOS) (IC 50 =10±2 μM) whereas it is poorly active towards inducible macrophage NOS (IC 50 >100 μM) . Bromocriptine is found to inhibit the activity of at least one human cytochrome P450 enzyme. Bromocriptine is a potent inhibitor of CYP3A4 with a calculated IC 50 value for the interaction of 1.69 μM.
Bromocriptine mesylate (2 mg/kg, i.p.) is administered for 7 days in groups of mice in forced swimming test (FST) and tail suspension test (TST). Bromocriptine group shows significant anti-immobility action as compared to control. When Bromocriptine administered 30 min after the last dose of 7 days MPE treatment and subjected to FST, this dopaminergic agonist produces significant and dose dependent potentiation of anti-immobility action of MPE (200 mg/kg, p.o.) as compared to MPE treatment alone. Bromocriptine treatment group shows a significant reduction of immobility time as compared to control. Bromocriptine administration after 7 days pretreatment with MPE (100 and 200 mg/kg, p.o.) shows significant and dose dependent potentiation of anti-immobility action of MPE as compared to MPE treatment alone. Intracisternal administration of Bromocriptine decreases significantly the static mechanical allodynia (SMA) score compared to that of sham (saline-injected rats) and its effect lasted for 30 min. Intraperitoneal administration of Bromocriptine induces a significant, dose dependent (0.1 mg and 1 mg/kg) decrease in pain scores in CCI-IoN group when compared to sham and its effect lasted for 6 h. The highest dose induces the highest score decrease (P<0.01). Bromocriptine effect lasts for 20 min. Intraperitoneal administration of Bromocriptine induces a significant dose dependent decrease in SMA score in CCI-IoN+6-OHDA lesioned group compared to that of sham. Its effect lasts for 6 h.
安全信息
危險(xiǎn)品標(biāo)志 | Xn |
---|---|
危險(xiǎn)類別碼 | 20/21/22 |
安全說明 | 22-24/25-36 |
危險(xiǎn)品運(yùn)輸編號(hào) | UN 3077 9 / PGIII |
WGK Germany | 3 |
RTECS號(hào) | KE1595000 |
F | 3-10 |
海關(guān)編碼 | 29396900 |
毒性 | LD50 in mice, rats, rabbits (mg/kg): 190, 72, 12.5 i.v. (Parkes) |
提供商 | 語言 |
---|---|
英文
|
更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
---|---|---|---|---|---|
2025/02/08 | HY-12705A | 甲磺酸溴隱亭 Bromocriptine mesylate | 22260-51-1 | 5 mg | 235元 |
2025/02/08 | HY-12705A | 甲磺酸溴隱亭 Bromocriptine mesylate | 22260-51-1 | 10mM * 1mLin DMSO | 273元 |